RNA-directed RNA polymerase L · SINGLE PROTEIN · Zaire ebolavirus (strain Mayinga-76) (ZEBOV) (Zaire Ebola virus)
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14RNA-directed RNA polymerase L shows approved-linked disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q05318. Start with COVID-19, then reuse UniProt Q05318 as the stable protein anchor across project notes and exports.
Start with COVID-19, then reuse UniProt Q05318 as the stable protein anchor across project notes and exports.
RNA-directed RNA polymerase L shows approved-linked disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with COVID-19 because it currently carries approved-linked support. Linked drugs include GALIDESIVIR, REMDESIVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyRNA-directed RNA polymerase L
Review this target as RNA-directed RNA polymerase L, mapped to UniProt Q05318. Sequence length is 2212 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RNA-directed RNA polymerase L as ChEMBL target CHEMBL4303062, mapped to UniProt Q05318. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether RNA-directed RNA polymerase L is the right protein anchor across sources, using UniProt Q05318 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why COVID-19 is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | RNA-directed RNA polymerase L |
| Target Type | SINGLE PROTEIN |
| Organism | Zaire ebolavirus (strain Mayinga-76) (ZEBOV) (Zaire Ebola virus) |
| UniProt | Q05318 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | RNA-directed RNA polymerase L |
| UniProt Accession | Q05318 |
| Component Type | Protein |
| Sequence Length | 2212 aa |
RNA-directed RNA polymerase L
Review this target as RNA-directed RNA polymerase L, mapped to UniProt Q05318. Sequence length is 2212 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
RNA-directed RNA polymerase L shows approved-linked disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block.
Start review with COVID-19 because it currently carries approved-linked support. Linked drugs include GALIDESIVIR, REMDESIVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.